Muscular dystrophy refers to more than 30 genetic conditions that cause progressive muscle weakness. Duchenne muscular dystrophy is the most common childhood form, affecting about 1 in 5,000 boys. Treatment has historically focused on managing symptoms and complications, but genetic therapies are now reaching patients.
What's actually going on in research
Trials are testing gene therapies that deliver a working copy of the dystrophin gene, exon-skipping drugs that restore partial dystrophin production, and drugs that boost utrophin to compensate for missing dystrophin. Corticosteroids remain standard treatment for Duchenne, and newer anti-inflammatory approaches aim to preserve muscle function with fewer side effects. Research also targets other dystrophy types, including limb-girdle and facioscapulohumeral muscular dystrophy.
Gene therapy
Several gene therapies are delivering a miniaturized dystrophin gene to muscle cells. Early results show some patients producing detectable dystrophin protein, though durability and functional benefit are still being studied.
Exon skipping
Four exon-skipping drugs are FDA-approved for Duchenne, each targeting different genetic mutations. New exon-skipping candidates aim to help a larger proportion of patients and produce more dystrophin protein.
Anti-inflammatory drugs
Researchers are testing alternatives to corticosteroids that might preserve muscle without causing weight gain, bone loss, and growth problems. Vamorolone showed promise in early trials.
What to know before you search
Eligibility typically depends on genetic mutation type, whether the person is still walking, heart and lung function, prior treatments including steroids, and sometimes age or antibody status for gene therapies.
What types of trials are currently open
- Gene therapy trials — Testing one-time infusions that deliver genetic material to muscle cells. These trials typically require heart and lung function above minimum thresholds.
- Exon-skipping trials — Testing drugs that modify how genetic instructions are read, allowing cells to produce a shortened but partially functional dystrophin protein.
- Drug trials — Testing medications that reduce inflammation, boost muscle growth, or protect heart and breathing muscles from damage.
- Natural history studies — Tracking how muscular dystrophy progresses over time to establish baselines for measuring whether new treatments slow decline.
- Biomarker studies — Looking for blood tests or imaging markers that could predict disease progression or treatment response.
Recently added Muscular Dystrophy trials
Metabolomic Biomarkers of Myotonic Dystrophy
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of myotonic dystrophy by examining a urine sample and a blood sample, and performing muscle function testing. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human myotonic dystrophy.
Track pain and movement changes over 6 months
1\. Brief Summary This prospective observational study aims to evaluate the 6-month longitudinal changes in chronic pain, pain characteristics, coping strategies, and functional performance in children and adolescents aged 7 to 18 years diagnosed with Duchenne Muscular Dystrophy (DMD), with a primary focus on comparing ambulatory and non-ambulatory disease stages. Pediatric DMD patients followed at the University of Health Sciences Antalya Training and Research Hospital Neuromuscular Diseases Center will undergo comprehensive evaluations at baseline (Month 0) and at 6 months follow-up (Month 6). Pain parameters will be evaluated using the Adolescent Pediatric Pain Tool (APPT) to assess pain intensity, body localization, and sensory/affective/evaluative/temporal qualities, and the Brief Pain Inventory (BPI) 7-item Pain Interference Scale to determine pain interference with daily activities. Pain coping strategies will be assessed using the Pediatric Pain Coping Inventory (PPCI, adolescent and parent versions). Functional and motor assessments will include the North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT), stair climb/descend tests, Vignos and Brooke scales, handgrip dynamometry, manual muscle testing (MMT), and range of motion (ROM) and contracture evaluations, alongside anthropometrics and quality of life. The central hypotheses are that non-ambulatory patients experience chronic pain more frequently, with longer duration, greater intensity, and across a higher number of anatomical sites than ambulatory patients. Furthermore, the study hypothesizes that anatomical pain sites, pain-aggravating and pain-relieving factors, and pain coping mechanisms differ significantly between ambulatory and non-ambulatory stages.
Find Muscular Dystrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.